Lantern Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	8.39	7.51	21.94	37.2	51.52	19.23
Short-Term Investments	3.97	16.5	19.36	17.99	19.2	-
Cash & Short-Term Investments	12.36	24.01	41.3	55.2	70.73	19.23
Cash Growth	-55.93%	-41.86%	-25.17%	-21.96%	267.80%	1460.78%
Other Current Assets	1.1	1.23	2.04	3.53	1.99	1.01
Total Current Assets	13.46	25.25	43.34	58.72	72.72	20.24
Net Property, Plant & Equipment	0.13	0.29	0.28	0.1	0.22	0.02
Other Long-Term Assets	0.04	0.04	0.03	0.02	1.02	0.1
Total Assets	13.63	25.57	43.65	58.84	73.95	20.36
Accounts Payable	3.95	4.14	2.51	2.75	2.17	0.55
Current Portion of Leases	0.09	0.19	0.17	0.05	0.15	-
Total Current Liabilities	4.04	4.33	2.68	2.8	2.33	0.55
Long-Term Debt	-	-	-	-	-	0.11
Long-Term Leases	-	0.05	0.06	-	0.05	-
Total Long-Term Liabilities	-	0.05	0.06	-	0.05	0.11
Total Liabilities	4.04	4.38	2.74	2.8	2.38	0.66
Common Stock	0	0	0	0	0	0
Additional Paid-in Capital	98.62	97.06	96.26	95.69	96.69	32.36
Accumulated Other Comprehensive Income	0.04	0.15	-0.11	-0.37	-0.09	-
Retained Earnings	-89.07	-76.03	-55.24	-39.28	-25.02	-12.66
Shareholders' Equity	9.59	21.19	40.91	56.04	71.57	19.7
Total Liabilities & Equity	13.63	25.57	43.65	58.84	73.95	20.36
Total Debt	0.09	0.24	0.23	0.05	0.2	0.11
Net Cash (Debt)	12.27	23.77	41.07	55.14	70.52	19.12
Net Cash Growth	-48.38%	-42.12%	-25.52%	-21.80%	268.82%	1451.97%
Net Cash Per Share	1.14	2.21	3.79	5.08	6.47	4.44
Book Value	9.59	21.19	40.91	56.04	71.57	19.7
Book Value Per Share	0.89	1.97	3.77	5.16	6.56	4.58
Tangible Book Value	9.59	21.19	40.91	56.04	71.57	19.7
Tangible Book Value Per Share	0.89	1.97	3.77	5.16	6.56	4.58

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q